The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global human insulin market reached a value of US$ 40.4 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 63.5 Billion by 2027, exhibiting a CAGR of 7.11% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Human insulin (HI) is a short-acting form of insulin used to treat hyperglycemia caused by type 1 and type 2 diabetes. It is produced by recombinant DNA technology and identical to endogenously made insulin. It is used to take the place of insulin generally produced by the body and aids in insulating sugar from the blood into other body tissues, wherein it is utilized for energy. It induces lower titers of circulating insulin antibodies and minimizes skin reactions. At present, manufacturers are introducing an inhalable form intended to be used as a bolus meal-time insulin.
Human Insulin Market Trends:
The increasing prevalence of diabetes on account of sedentary lifestyles, unhealthy dietary patterns, and high-stress levels represents one of the major factors positively influencing the demand for HI around the world. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. In addition, key players are introducing pen devices and safety pen needles to administer HI in the body. It assists in minimizing discomfort and reducing the risks of injuries, infections, and bloodborne pathogen transmission. Apart from this, the growing public awareness about the benefits of using HI and the increasing health consciousness among individuals is driving the market. Besides this, significant improvements in the healthcare infrastructure and extensive research and development (R&D) activities in the field of biotechnology conducted by leading industry players are creating a positive outlook in the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global human insulin market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, distribution channel and disease type.
Breakup by Product Type:
Breakup by Distribution Channel:
Breakup by Disease Type:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being B. Braun Melsungen AG, Becton, Dickinson and Company (BD), Biocon, Eli Lilly and Company, Gulf Pharmaceutical Industries (Julphar), Novo Nordisk A/S, Pfizer Inc., Groupe Sanofi, SEDICO Co., Wockhardt Limited, Ypsomed AG, etc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product Type, Distribution Channel, Disease Type, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||B. Braun Melsungen AG, Becton, Dickinson and Company (BD), Biocon, Eli Lilly and Company, Gulf Pharmaceutical Industries (Julphar), Novo Nordisk A/S, Pfizer Inc., Groupe Sanofi, SEDICO Co., Wockhardt Limited and Ypsomed AG|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at